1 / 7

Phase 2

Phase 2. Treatment Experienced (with Sofosbuvir and Ribavirin). Retreatment of Sofosbuvir + Ribavirin Failure with Sofosbuvir-Containing Regimens in Patients with Genotype 2 or 3 . Esteban R, et al . 49 th EASL; April 2014. Abstract 08.

shana
Télécharger la présentation

Phase 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentExperienced (with Sofosbuvir and Ribavirin) Retreatment of Sofosbuvir + Ribavirin Failure with Sofosbuvir-Containing Regimens in Patients with Genotype 2or 3 Esteban R, et al. 49thEASL; April 2014. Abstract 08.

  2. Retreatment of SOF + RBV Failure with SOF-Containing Regimens in GT 2 or 3Study Features Source: Esteban R, et al. 49th EASL; April 2014. Abstract 08.

  3. Retreatment of SOF + RBV Failure with SOF-Containing Regimens in GT 2 or 3Baseline Characteristics Source: Esteban R, et al. 49th EASL; April 2014. Abstract 08.

  4. Retreatment of SOF + RBV Failure with SOF-Containing Regimens in GT 2 or 3Study Design Week 0 12 24 36 GT2 or GT3 Sofosbuvir + PEG + RBV N = 34 SVR12 Sofosbuvir + RBV N = 73 SVR12 Drug DosingSofosbuvir: 400 mg once dailyPeginterferon alfa-2a: 180 µg once weeklyWeight-based Ribavirin (in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Esteban R, et al. 49th EASL; April 2014. Abstract 08.

  5. Retreatment of SOF + RBV Failure with SOF-Containing Regimens in GT 2 or 3Results, by Genotype SVR12 by Regimen and HCV Genotype 24/26 25/40 4/4 1/2 20/22 24/38 Source: Esteban R, et al. 49th EASL; April 2014. Abstract 08.

  6. Retreatment of SOF + RBV Failure with SOF-Containing Regimens in GT 2 or 3Results, by Genotype SVR12 by Regimen and HCV Genotype 4/4 1/2 20/22 24/38 Source: Esteban R, et al. 49th EASL; April 2014. Abstract 08.

  7. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related